Mologen Ag

Gilead Sciences, Inc.

Kerstin Kapp

Matthias Schroff

Manuel Schmidt

Alfredo Zurlo

Burghardt Wittig

Rasmus Offersen

Christiane Kleuss

Ole Schmeltz Sogaard

Martin Tolstrup

The invention relates to a non-coding sequence of deoxyribonucleic acids comprising at least one sequence motif NNCGNN, wherein N is a nucleotide comprising A, C, T, or G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxy-thymidine for the treatment of viral infections. In particular, the non-coding sequence of deoxyribonucleic acids is used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors.

Methods of treating a retroviral infection

The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.

Combination comprising immunostimulatory oligonucleotides

The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAGS, CD137(4-1BB) and a non-codiung immuno-modulating DNA.

The present invention relates to a covalently closed DNA construct, a pharmaceutical composition and a vaccine and their use for the modulation of the immune system. It provides a DNA construct for immunomodulation comprising a specific DNA sequence.

Covalently closed non-coding immunomodulatory DNA construct

The present invention relates generally to the identification of patients suffering from cancer whether they will respond to specific therapies. More particularly the invention relates to a method and means for identifying responder to a therapy TLR-9 agonists.

Growing community of inventors

Berlin, Germany

Kerstin Kapp